Page 12 - Les meilleurs doctors en Turquie pour votre IRM d’une zone - TOP 322 des médecins

Dr. Burak Onvural is a board-certified microsurgeon in orthopedics and traumatology. He has over 17 years of clinical experience. He is known for his skills in treating sports injuries, joint replacements, and minimally invasive procedures such as knee and hip arthroscopy.

Dr. Onvural has worked as an orthopedic doctor for top sports clubs, including Altay FC in the Turkish Premier League. He has performed many successful surgeries, including anterior cruciate ligament reconstructions and stem cell therapies for arthritis. He received international training at the International Trauma Association in Switzerland. He is also accredited by leading orthopedic societies.

Dr. Metin Kızılkaya is a specialist in Oral and Maxillofacial Surgery. He graduated from Istanbul University Faculty of Dentistry. He completed his doctorate at Başkent University, where he studied the effects of ibandronic acid on alveolar bone after tooth extraction. Dr. Kızılkaya has been practicing at Dent Suadiye since 2016.

He is a member of the Turkish Oral and Maxillofacial Surgery Society and the International Team of Implantology (ITI). Dr. Kızılkaya is dedicated to ongoing professional growth in implantology and surgical dentistry.

Dr. Ilker Arslan is a specialist in prosthodontics and implantology. He is known for his skills in aesthetic dentistry. Dr. Arslan is a member of the Turkish Prosthodontics and Implantology Association (TPID), the International Team for Implantology (ITI), and the Turkish Academy of Aesthetic Dentistry (EDAD).

He is dedicated to ongoing training and follows international standards in dental care. His memberships show his commitment to new treatment methods and quality results for his patients in prosthodontics and implantology.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Professor Dr. Cenap Zeybek is a respected Pediatric Cardiologist known for his skill in advanced heart procedures. He became an Associate Professor in 2011. In 2017, he was promoted to Professor. This shows his expertise and leadership in pediatric cardiology. Dr. Zeybek has performed many complex surgeries, such as heart valve replacements, open heart operations, and interventional procedures. His work has helped improve outcomes for children with heart conditions.

He has published many scientific articles and given several presentations. This shows his dedication to improving pediatric heart care. Dr. Zeybek’s qualifications and academic success make him a leading expert in his field.

Areas of Interests

• General Neurology
• Clinical Neurophysiological examinations (Electromyography, evoked potentials, electroencephalography, polysomnography)
• Peripheral Nervous System Diseases
• Muscle diseases
• Epilepsy
• Headache
• Sleep and sleep disorders
• Migraine botox and botulinum A toxin applications

Education:

• 1980-1985 Atatürk Elementary School
• 1985-1988 Anamur High School
• 1988-1991 Anamur High School
• 1991-1998 Marmara University Faculty of Medicine in English
• 2000- 2004 PTT Education and Research Hospital Neurology Clinic (Medical Specialization Student)
• 2007-2010 Istanbul University Health Sciences Experimental Medicine Research Institute Electroneurophysiology Master's Program
• 2012- Clinical Neurophysiology Sub-branch Specialist

Experiences:

• September 2023-Currently Haliç University Faculty of Medicine, Faculty Member
• January 2023-Currently Hisar Intercontinental Hospital, Department of Neurology
• 2014- August 2023 Bilgi University Health Sciences Vocational School Electroneurophysiology Department, Faculty Member
• 2019- 2022 Ataşehir Private Avicenna Hospital, Neurology Department
• 2009-2018 Fatih Sultan Mehmet Education and Research Hospital Neurophysiology Laboratory (Specialist Doctor)
• 2007-2010 Istanbul University Health Sciences Experimental Medicine Research Institute Electroneurophysiology Master's Program
• 2005-2006 Istanbul University Istanbul Faculty of Medicine Department of Neurology Electrodiagnostics Department EMG Laboratory
• 2000-2004 PTT Education and Research Hospital Neurology Clinic (Specialist Student in Medicine)

Areas of Interests

• Demyelinating Diseases and MS
• Peripheral Neuropathy and Motor Neuron Disease (ALS)
• Neuromuscular Junction Diseases (MG)

Education 

• M.Sc. Faculty of Medicine, Ondokuz Mayıs University  1990
• Specialization in Medicine  Neurology,  Ankara Training and Research Hospital 1997
• Minor Specialization  Clinical Neurophysiology, Medical Specialization Board 2011

Experience

• Doctor MoH Kastamonu and Samsun Health Center No. 7 1990-1992
• Dr. Res.Assist. Ankara Training and Research Hospital Neurology Clinic 1992-1997
• Assoc. Dr. Abant İzzet Baysal University Düzce Faculty of Medicine 1999-2006
• Assoc.Dr. Duzce University Faculty of Medicine 2007-2011
• Prof.Dr  Duzce University Faculty of Medicine  2011-

Domaines d'intérêt

• Chirurgie reconstructive urogénitale pédiatrique
• Hypospadias
• Circumcision
• Chirurgie oncologique
• Anomalies congénitales du système urinaire supérieur et inférieur
• Chirurgie du nouveau-né
• Chirurgie abdominale pédiatrique

Formation
 

• 1997 - Université 19 Mayıs
• 1998 - Congrès national de chirurgie pédiatrique, Meilleure étude de recherche
• 2001 - Université Kocaeli
• 2007 - Gouvernement du Kosovo
• 2009 - Université Yeditepe
• 2009 - Congrès d'Arabie Saoudite, Meilleure étude clinique

Expérience
 

• Lycée FMV Işık
• Faculté de médecine de l’Université d’Istanbul Cerrahpaşa
• Université Ondokuz Mayıs
• Hôpital pour enfants Zeynep Kamil
• Faculté de médecine de l’Université Kocaeli
• UT Southwestern Medical Center, urologie pédiatrique, Dallas, USA
• Centre médical de l’Université Ege, urologie pédiatrique
• Université Yeditepe

Le Prof. Dr. Selami Sozubir est l’auteur de 65 publications scientifiques, ayant reçu plus de 11 000 lectures et près de 1 000 citations, ce qui témoigne de sa contribution importante dans le domaine de la chirurgie et de l’urologie pédiatriques.

Areas of Interests

• Neuro-oncological surgery
• Spinal Surgery
• Pediatric Neurosurgery
• Peripheral Nerve Surgery
• Functional Neurosurgery and Algology

Education:

• Istanbul University, Faculty of Medicine
• Istanbul Okmeydani Training and Research Hospital

Experience:

• Liv Hospital Ulus
• Sisli Kolan Hospital
• Prof.Dr.Cemil Taşcıoğlu City Hospital
• Ardahan State Hospital

Research:

• Tumor markers and other laboratory findings in brain tumors
• Antiepileptic drugs in operated brain tumors
• Cervical corpectomy techniques
• Pre-emptive analgesia in spine surgeries

Publications:

• Uysal E, Cine HS, Yavuz AY, Cal MA. Impact of subventricular zone interaction on clinical outcomes in patients with intracerebral hematoma. Experimental Biomedical Research, 2024;7(3): 117–126. https://doi.org/10.30714/j-ebr.2024.215
• Çal MA, Yangı K. A Single-center Study Comparing Volumetric and Morphometric Measurements of Chiari Malformation in the Turkish Population. Eur Arc Med Res.2024 Mar;40(1):50-56. doi:10.4274/eamr.galenos.2024.24892.
• Avcı İ, Başkurt O, Şeker S, Kurtuluş Y, Çal MA. Rapid Recurrence of Glioblastoma After 12 Days Despite Gross Total Resection. Eur Arc Med Res.2024 Mar;40(1):62-65. doi:10.4274/eamr.galenos.2024.48615.
• Play MA. The relationship between vertebral compression rates and systemic inflammatory scores in osteoporotic vertebral fractures. Eur Rev Med Pharmacol Sci. 2024;28(3):959-968. doi:10.26355/eurrev_202402_35333
• Çal MA, Gök H. Retrospective Evaluation of the Effect of Surgery and CyberKnife on Recurrence and Neurological Deficits in Cases Diagnosed as Vestibular Schwannoma. Haydarpasa Numune Med J.2023;63 (1), 62 ‑67.doi:10.14744/hnhj.2022.45712
• Uysal E, Çal MA, Cine HS. The use of vancomycin powder in the compound depressed skull fractures. Clin Neurol Neurosurg. 2023;225:107570. doi:10.1016/j.clineuro.2022.107570
• Gök H, Şeker S, Peker HO, Çal MA, Altay T, Çelik S. A rare case report: Cervical subcutaneous and mediastinal emphysema due to mastoid fracture. A rare case report: Cervical subcutaneous and mediastinal emphysema due to mastoid fracture. Ulus Travma Emergency Surgery Journal . 2020;26(2):328 ‑330. doi:10.14744/tjtes.2019.02828
• Çınar N,Karaoğlan A,Midi A,Çal MA,Kelten B,Çakmak MA,Şahin Ş. Neuroprotective effect of ziprasidone: Preliminary results compared to haloperidol. J. Exp. Clin. Med ., 2014; 31:71 ‑75. doi : 10.5835/jecm.omu.31.02.002
• Karaoglan A, Cal MA, Orki A, Arpaozu BM, Colak A. Pneumorrhachis associated with bronchial asthma , subcutaneous emphysema and pneumomediastinum . Turkish Neurosurg . 2011;21(4):666 ‑668.
• Kelten B, Karaoğlan A, Cal MA, Akdemir O, Karancı T. Human immunodeficiency Bilateral epidural puncture in a patient infected with the virus Hematoma : Case report [ Bilateral epidural hematoma in a patient with Human immunodeficiency virus infection : a case report ]. Ulus Trauma Emergency Surgery Journal . 2013;19(3):267 ‑270. doi: 10.5505 /tjtes.2013.49799
• Karaoglan A, Akdemir O, Cinar N, et al. Correlation between leptin and pro- ‑inflammatory cytokines in cortical contusion injury model. Ulus Trauma Emergency Surgery Journal . 2011;17(4):298 ‑302. doi: 10.5505 /tjtes.2011.69077
• Cal MA, Kelten B, Akbas A, Akdemir O, Karaoglan A. Coexistence of spinal lipoma, ependymal cyst and dermoid cyst in neighboring localizations in context medullaris : A case report . HealthMed . 2013; 7(12):3227
• Canpolat A, Duman H, Akbaş A, Çal MA, Akdemir AO. Diffuse dysphagia and myeloradiculopathy presenting idiopathic skeletal hyperosteosis ( Forestier Disease). TC Maltepe University Medical Faculty Journal.2012;4(2),14 ‑17
• Karaoglan A, Kelten B,Akdemir AO,Çal MA. Lumbar spine presenting with radiculopathy spinal Chondroma : Case report. TC Maltepe University Medical Faculty Journal. 2011;3(3),28 ‑30
•  
• Istanbul Medical Chamber
• Turkish Neurosurgery Association
   

Spécialisé dans les troubles neurologiques, le traitement et la réadaptation. Traite l’épilepsie, les troubles du sommeil, les maux de tête, les maladies cérébrovasculaires et les problèmes de mouvement.

Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.

He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.

Dr. Cengiz Sen is an Orthopedics and Traumatology specialist. He has expertise in revision arthroplasty, degenerative joint disease, congenital limb deformities, and pediatric orthopedic disorders. Dr. Sen is skilled in limb lengthening, pseudoarthrosis surgery, and managing periprosthetic infections. He is also a pioneer in using stem cell therapy for orthopedic conditions.

Dr. Sen has published many articles, especially on total knee replacement and infected nonunion. He is a professor at Istanbul University Faculty of Medicine. He has received the AOTT Oral Presentation Award for his academic and clinical achievements.

Éducation:

• Enseignement supérieur (6 ans) : Faculté de médecine de l'Université de Marmara, 2001
• Spécialisation en médecine : Faculté de médecine de l'Université d'Istanbul, 2007
  

Expérience:

• Faculté de médecine, Université de Rostock, Département de chirurgie cardiaque - Assistant de recherche, août 2007 - août 2008
• Hôpital spécialisé et centre de recherche King Faisal, Institut cardiaque King Faisal - Fellow, août 2008 - octobre 2008
• Hôpital privé Göztepe Şafak, octobre 2008 - avril 2009
• Hôpital privé Esnaf, mai 2009 - mars 2010
• Hôpital d'État de Düzce Atatürk, mars 2010 - septembre 2011
• Hôpital privé Anadolu Medical Center, octobre 2011 - juin 2013
• Université d'Istanbul Faculté de médecine d'Istanbul, juillet 2013 - décembre 2018
• Faculté de médecine de l'Université Medipol d'Istanbul, janvier 2019 - avril 2023
• Faculté de médecine de l'Université de Biruni, avril 2023 - aujourd'hui
• Professeur : 18 décembre 2020
• Professeur associé : 16 avril 2015 - 18 décembre 2020
• Médecin spécialiste : novembre 2009 – 16 avril 2015
• Assistante de recherche : juin 2002 - juillet 2007
• Faculté de médecine : Université de Marmara - Anglais (1995-2001) [Note du diplôme : 75/100 ] - Répertoriée dans le World Directory of Medical Schools.

Récompenses :

Deuxième prix de la meilleure présentation orale : Didem Melis Öztaş, Mert Meriç, Metin Onur Beyaz, Mehmet Akif Onalan, Shiraslan Bakhshaliyev, Kıvılcım Sönmez, Kerem Oter, Sedat Ziyade, Beyhan Ömer, Ufuk Alpagut, Murat Uğurlucan. Étude de l'effet de l'érythropoïétine sur les niveaux de cellules souches dans les tissus cardiovasculaires chez les rats diabétiques. 19e Congrès national de chirurgie vasculaire et endovasculaire, Kyrenia, Chypre, du 26 au 29 octobre 2019.

Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.

Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.

Éducation

• Licence : Faculté de médecine d'Istanbul, Université d'Istanbul, 2007
• MSc (Département de médecine interne) : Faculté de médecine de l'Université de Marmara, 2012
• Doctorat (clinique d'hématologie) : Hôpital de formation et de recherche d'Istanbul, 2018
• Professeur associé (clinique d'hématologie) : Prof.Dr.Cemil Tascioglu, hôpital de formation et de recherche, 2019

Français Le Prof. Dr. Rafet Eren a obtenu son diplôme de la Faculté de Médecine d'Istanbul en 2007. Il a terminé sa formation de spécialité en médecine interne à la Faculté de Médecine de l'Université de Marmara en 2012. En 2018, il est devenu sous-spécialiste en hématologie à l'Hôpital de Formation et de Recherche d'Istanbul. En 2019, il a reçu le titre de professeur associé dans le domaine de l'hématologie. Par la suite, il a travaillé comme membre du corps enseignant à l'hôpital de Başakşehir Çam et Sakura City, à l'hôpital de formation et de recherche de Bozyaka et à l'Université d'Istinye (Université d'Istinye Bahçeşehir et Hôpital Liv Vadistanbul) et travaille actuellement à l'hôpital universitaire de Biruni. Le Dr Rafet Eren est membre de la Société turque d'hématologie, de la Société de spécialité en hématologie et de la Société européenne d'hématologie et parle couramment l'anglais. Il a environ 50 publications dans des revues à comité de lecture nationales et internationales.

Adhésions scientifiques

• Association turque d'hématologie
• Société de Spécialité en Hématologie
• Société turque de spécialité en médecine interne
• Société européenne d'hématologie

Récompenses

• Prix du jeune chercheur (42e Congrès national d'hématologie), 2016
• Prix spécial du jury (3e Congrès d'oncologie hématologique), 2015
• Communication 3e prix (2e Symposium sur l'hémato-oncologie et la transplantation de moelle osseuse), 2016

Éducation

Faculté de médecine de l'Université de GATA, doctorat en éducation médicale, 1984, Ankara/Istanbul
Faculté de médecine de l'Université de GATA, résidence en neurologie, 1992, Ankara/Istanbul

Expérience

Étudiant en spécialisation au département de neurologie du GATA (1987-1992, Ankara/Turquie)
Professeur adjoint au département de neurologie du GATA (1992-1995, Ankara/Turquie)
Médecin-chef et spécialiste en neurologie à l'hôpital aérien de KüTahya (1995-2003, Kütahya/Turquie)
Spécialiste en neurologie à l'hôpital Şişli Memorial (2004-2021, Istanbul/Turquie)

J'ai terminé mes études primaires, secondaires et secondaires à Konya, ma ville natale, et mes études de médecine et de spécialité médicale à Ankara GATA. J'ai reçu une formation en médecine de vol et j'ai travaillé comme médecin de vol dans les secteurs militaire et civil. J'ai reçu une formation de photographie débutante et avancée et j'ai ouvert 4 expositions de photographie. J'ai fait des études de photographie dans 56 pays en Turquie et dans 56 pays que j'ai eu l'occasion de visiter.

Adhésions scientifiques

Association médicale turque
Membres du conseil d'administration de la DGCA

Éducation

Médecin : Centre de santé n°1 Kilis Merkez, 2006-2008
Médecin assistant : Faculté de médecine de l'Université de Mersin, 2009-2013
Médecin spécialiste : Hôpital d'État de Bingöl Genç, 2013-2014
Assistant mineur : Faculté de médecine de l'Université d'Akdeniz, 2014-2017
Spécialiste mineur : Hôpital régional de formation et de recherche d'Erzurum, 2017-2018
Spécialiste en médecine interne : Hôpital de formation et de recherche de Gaziosmanpaşa, 2018-2020
Spécialiste traitant : Başakşehir Çam et hôpital municipal de Sakura, 2020-2022
Professeur agrégé : Başakşehir Çam et hôpital municipal de Sakura, 2023
Professeur agrégé : Hôpital Medicalpark Gaziosmanpaşa de l'Université Istinye, 2023-2024

Adhésions scientifiques

Société turque de pédiatrie
Société turque de gastroentérologie, d'hépatologie et de nutrition pédiatriques
ESPGHAN - Société européenne de gastroentérologie, d'hépatologie et de nutrition pédiatriques.

Intérêts médicaux

• 
  -Syndrome du côlon irritable (sans repos)
• -Allergies alimentaires associées au système digestif
• -Constipation, incontinence fécale
• -Diarrhée aiguë et chronique, malabsorption
• -Douleurs abdominales chroniques
• -Reflux gastro-œsophagien
• - Maladie cœliaque
• -Colite ulcéreuse, maladie de Crohn
• -Traitement avant et après transplantation hépatique
• - Pancréatite aiguë et chronique